Ivy Life Sciences, Co., Ltd   Report issue

For profit Phase 3
Founded: New Tapei City Taiwan (2008)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2008
NCT03515252
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Ivy Life Sciences, Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic natural killer cells (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1